Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development
Go back to Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 485.65 -0.38 (0.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $486.03 | 52 Week High | $134.71 | |||
| Open | $483.51 | 52 Week Low | $73.31 | |||
| Day High | $496.69 | P/E | N/A | |||
| Day Low | $481.98 | EPS | $-1.98 | |||
| Volume | 1,568,123 | |||||
